Why Ionis Pharmaceuticals, Inc. (IONS) stock moved
Ionis Pharmaceuticals, Inc. (IONS) shares fell 1.2% to $54.62 as of July 29, 2026, a modest decline from the prior close of $55.30. BestStocks flagged the session as a major change for IONS. The move is tied to an earnings beat. Below, we break down what changed for IONS, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
Ionis Pharmaceuticals, Inc. (IONS) reported EPS of −$0.43 vs. consensus estimate of −$1.08, beating expectations by 60.2% on 2026-07-29. IONS earnings scheduled for 2026-08-05 with consensus EPS estimate of −$0.91.
What it means for Ionis Pharmaceuticals, Inc. investors
For Ionis Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Earnings beat — stock sold off (sell-the-news reaction); Ionis Pharmaceuticals, Inc. (IONS) moved +1.16% from $53.39 to $54.01 on 2026-07-22. Weighing against that: Negative session, down 1.2%; Ionis fell 3.17% to $51.70 after the CARDIO-TTRansform phase 3 trial for Wainua (its partnered ATTR-CM drug) missed its primary endpoint, according to reporting on the trial readout. Wall Street's consensus price target sits at $94.58, implying +73.2% upside from $54.62. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality low (52/100). With earnings roughly 98 days out, the next report is the most likely near-term test of the move.
IONS price reaction
IONS last traded at $54.62, down $0.68 (-1.23%) from the previous close of $55.30. The session traded on 0.6× average volume (below avg), so participation was unremarkable.
Bullish and bearish analyst opinions on Ionis Pharmaceuticals, Inc. (IONS)
The consensus analyst price target on Ionis Pharmaceuticals, Inc. (IONS) is $94.58, 73.2% above the recent $54.62. Over the past 90 days analysts logged 0 upgrades, 18 maintains, and 1 downgrade. Here is how the bullish and bearish cases on IONS line up.
The bullish case
- Wall Street's consensus price target of $94.58 implies +73.2% upside from $54.62.
- The Street's most bullish target is $130.00 (+138.0%).
- Earnings beat — stock sold off (sell-the-news reaction).
- Ionis Pharmaceuticals, Inc. (IONS) moved +1.16% from $53.39 to $54.01 on 2026-07-22.
The bearish case
- 1 analyst downgrade in the past 90 days, most recently Wolfe Research to Peer Perform (2026-07-16).
- Negative session, down 1.2%.
- Ionis fell 3.17% to $51.70 after the CARDIO-TTRansform phase 3 trial for Wainua (its partnered ATTR-CM drug) missed its primary endpoint, according to reporting on the trial readout.
- Ionis Pharmaceuticals announced Thursday that its Phase 3 CARDIO-TTRansform trial of eplontersen (Wainua), developed with partner AstraZeneca for transthyretin-mediated amyloid cardiomyopathy, failed to meet its primary endpoint of reducing cardiovascular deaths and recurring heart problems (Reuters, Barron's).
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for IONS
Frequently asked questions about IONS
Why did Ionis Pharmaceuticals, Inc. (IONS) stock move?
IONS fell 1.2% to $54.62. The move is associated with an earnings beat.
How much did IONS stock fall?
IONS lost 1.23% ($0.68) versus the prior close of $55.30, last trading at $54.62 on 0.6× average volume.
When is Ionis Pharmaceuticals, Inc.'s next earnings date?
IONS's next earnings report is estimated for 2026-11-04 — about 98 days away.
What is the analyst price target for IONS?
The consensus analyst price target for IONS is $94.58, about 73.2% above the current $54.62. Over the past 90 days, analysts recorded 0 upgrades, 18 maintains, and 1 downgrade.
How BestStocks tracks IONS
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for IONS, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
